“Development of Dual Responsive Formulation for Targeted Delivery of siRNA to Breast Cancer Sites”

Ivanenko Liudmyla

“Development of Dual Responsive Formulation for Targeted Delivery of siRNA to Breast Cancer Sites”

Authors: Ivanenko Liudmyla

Published: 2025-03-06 12:15:00.108

Abstract

The development of an advanced dual-responsive drug delivery system is critical in addressing the limitations of conventional cancer treatments, such as non-specific adverse effects and poor targeting. This study explores the use of gold-coated superparamagnetic iron oxide nanoparticles (Au-SPIONs) integrated with chitosan microspheres for the targeted delivery of small interfering RNA (siRNA) to breast cancer sites. The formulation's performance is assessed by examining encapsulation efficiency, drug loading capacity, release kinetics, and dual-responsive characteristics under both pH and magnetic stimuli. Experimental analysis demonstrates that Au-SPIONs significantly enhance siRNA encapsulation, medium molecular weight chitosan optimizes drug loading, and controlled crosslinker concentration regulates sustained release. The dual-responsive nature of the system provides enhanced targeting precision compared to traditional delivery systems. These findings suggest that this innovative formulation holds promise for improving the efficacy of siRNA-based breast cancer therapies, although further clinical studies are necessary to validate its real-world applicability.

Keywords

siRNA delivery, breast cancer therapy, nanoparticles, chitosan microspheres, Au-SPIONs, dual-responsive system, drug encapsulation, targeted drug delivery, controlled release, polymer-based drug carriers

References

Peer, D., Karp, J. M., Hong, S., Farokhzad, O. C., Margalit, R., & Langer, R. (2007). Nanocarriers as an emerging platform for cancer therapy. Nature Nanotechnology, 2(12), 751–760. https://doi.org/10.1038/nnano.2007.387
Alexis, F., Pridgen, E., Molnar, L. K., & Farokhzad, O. C. (2008). Factors affecting the clearance and biodistribution of polymeric nanoparticles. Molecular Pharmaceutics, 5(4), 505–515. https://doi.org/10.1021/mp800051m
Xie, J., Lee, S., & Chen, X. (2010). Nanoparticle-based theranostic agents. Advanced Drug Delivery Reviews, 62(11), 1064–1079. https://doi.org/10.1016/j.addr.2010.07.009
Davis, M. E., Chen, Z. G., & Shin, D. M. (2008). Nanoparticle therapeutics: An emerging treatment modality for cancer. Nature Reviews Drug Discovery, 7(9), 771–782. https://doi.org/10.1038/nrd2614
Kim, D., Jeong, Y. Y., Jon, S. (2010). A drug-loaded aptamer-gold nanoparticle bioconjugate for targeted cancer therapy. Journal of the American Chemical Society, 132(30), 9984–9986. https://doi.org/10.1021/ja102209x
Liu, G., Gao, J., Ai, H., & Chen, X. (2013). Applications and potential toxicity of magnetic iron oxide nanoparticles. Small, 9(9–10), 1533–1545. https://doi.org/10.1002/smll.201201531
Medina, C., Santos-Martinez, M. J., Radomski, A., Corrigan, O. I., & Radomski, M. W. (2007). Nanoparticles: Pharmacological and toxicological significance. British Journal of Pharmacology, 150(5), 552–558. https://doi.org/10.1038/sj.bjp.0707130
Tang, Z., He, C., Tian, H., Ding, J., & Chen, X. (2016). Polymeric nanostructured materials for biomedical applications. Progress in Polymer Science, 60, 86–128. https://doi.org/10.1016/j.progpolymsci.2016.03.002
Singh, R., & Lillard, J. W. (2009). Nanoparticle-based targeted drug delivery. Experimental and Molecular Pathology, 86(3), 215–223. https://doi.org/10.1016/j.yexmp.2008.12.004
Jain, R. K., Stylianopoulos, T. (2010). Delivering nanomedicine to solid tumors. Nature Reviews Clinical Oncology, 7(11), 653–664. https://doi.org/10.1038/nrclinonc.2010.139

Download PDF

How to Cite

Ivanenko Liudmyla, (2025-03-06 12:15:00.108). “Development of Dual Responsive Formulation for Targeted Delivery of siRNA to Breast Cancer Sites”. JANOLI International Journal of Pharmaceuticals and Chemicals, Volume t8VTiGjctuTvNUTp50bc, Issue 1.

ISSN: A/F

JANOLI International Journal of
Pharmaceuticals and Chemicals ( JIJPC )